Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC

Author:

Kirstein Mark N.,Panetta John C.,Gajjar Amar,Nair Geeta,Iacono Lisa C.,Freeman Burgess B.,Stewart Clinton F.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Reference19 articles.

1. Brandes AA, Pasetto LM, Monfardini S (2000) New drugs in recurrent high grade gliomas. Anticancer Res 20:1913

2. Prados MD (2000) Future directions in the treatment of malignant gliomas with temozolomide. Semin Oncol 27:41

3. Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, Dugan M, Cutler D, Batra V, Grochow LB, Donehower RC, Rowinsky EK (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309

4. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hofman R, Stevens MFG, Brampton MH, Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287

5. Reid JM, Stevens DC, Rubin J, Ames MM (1997) Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following the administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3:2393

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3